15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Goodrx Holdings Inc, 3 rate it Buy or better, 6 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets range widely, $2.50 to $5.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $3.58 sits 15% above the current $3.12. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.08 next quarter toward $0.36 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Hold
Strong Buy00%
Buy330%
Hold660%
Sell110%
Strong Sell00%
Based on 10 analysts giving stock ratings to Goodrx Holdings Inc.
As of Jul, 3 of 10 firms rate GDRX a Buy (6 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
GDRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.08
Range $0.07 – $0.09 · 12 analysts · -0% YoY
Next period, 12 analysts expect Goodrx Holdings Inc to earn $0.08 a share (range $0.07 – $0.09), versus $0.08 a year earlier. Full-year consensus is $0.31, growing to $0.36 the year after.
REVENUE · NEXT QUARTER
$194.0M
Range $188.3M – $198.2M · 12 analysts · -1% YoY
Revenue is expected to reach $194.0M (range $188.3M – $198.2M), -1.1% year-over-year. Full-year consensus is $775.9M, rising to $817.9M next year.
Top analysts covering Goodrx Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GDRX.
#1
Eric Sheridan
Goldman Sachs · Rank #341
Hold
$3.50+12.4% to target
Overall win rate
32%
+ Follow
#2
Scott Schoenhaus
Keybanc · Rank #345
Buy
$6.00+92.6% to target
Overall win rate
29%
+ Follow
#3
Daniel Grosslight
Citigroup
Buy
$4.00+28.4% to target
Coverage
—
+ Follow
#4
Kevin Caliendo
UBS
Hold
$2.00-35.8% to target
Coverage
—
+ Follow
#5
Stan Berenshteyn
Wells Fargo
Buy
$3.50+12.4% to target
Coverage
—
+ Follow
GDRX stock forecast FAQ
What is GDRX's average 12-month price target?+
The 9 analysts with a live target average $3.58 for Goodrx Holdings Inc over the next 12 months, ranging from a $5.00 high to a $2.50 low.
Is GDRX stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 10 analyst ratings, 3 are Buy or Strong Buy, 6 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for GDRX?+
The Street-high target is $5.00, and the Street-low is $2.50 (Goldman Sachs). The average of all 9 active targets is $3.58.
How many Wall Street analysts cover GDRX?+
10 analysts have an active rating on Goodrx Holdings Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering GDRX?+
Among analysts who currently cover GDRX, Eric Sheridan of Goldman Sachs has the strongest overall Quantellect track record (Rank #341). Their current call is Hold with a $3.50 target.
What is Goodrx Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $0.08 per share (range $0.07 – $0.09) across 12 analysts. Full-year EPS is projected at $0.31, rising to $0.36 the following year.
How much revenue is Goodrx Holdings Inc expected to report next quarter?+
Consensus revenue is $194.0M (range $188.3M – $198.2M). Full-year revenue is projected at $775.9M, growing to $817.9M next year.
Have analysts been upgrading or downgrading GDRX lately?+
As of Jul, 3 of 10 firms rate GDRX a Buy (6 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GDRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
